CRISPR BUY OR NOT TO BUY..?
Güncellendi
Third Quarter 2021 Financial Results
• Cash Position: Cash, cash equivalents, and marketable securities were $2,477.4 million as of
September 30, 2021, compared to $2,589.4 million as of June 30, 2021. The decrease in cash of
$112.0 million was primarily driven by cash used in operating activities to support ongoing
research and development of the Company’s clinical and pre-clinical programs.
• Revenue: Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to
$0.1 million for the third quarter of 2020. Collaboration revenue primarily consisted of revenue
recognized in connection with our collaboration agreements with Vertex.
• R&D Expenses: R&D expenses were $105.3 million for the third quarter of 2021, compared to
$71.0 million for the third quarter of 2020. The increase in expense was driven by the development
activities supporting the advancement of the hemoglobinopathies program and wholly-owned
immuno-oncology programs, as well as increased headcount and supporting facilities, related
expenses.
• G&A Expenses: General and administrative expenses were $24.4 million for the third quarter of
2021, compared to $21.5 million for the third quarter of 2020. The increase in general and
administrative expenses for the year was primarily driven by headcount-related expenses.
• Net Loss: Net loss was $127.2 million for the third quarter of 2021, compared to a net loss of
$92.4 million for the third quarter of 2020.
https://crisprtx.gcs-web.com/static-files/2b9c5e50-091f-4103-bc29-f7c87de56f6e
MACD: BEARISH CROSS
RSI: OVERSOLD
VOLUME: LOW
CURRENT SUPPORT @ 1.272 FIB
1.618 IS YOUR IMPULSE TARGET FOR A BREAK IN EITHER DIRECTION
Puzzled on this one honestly, looks like it wants to go lower, but we'll see at the weekly close. Keep an eye on the SPY index.
DYOR
PRACTICE RISK MANAGEMENT
GOOD LUCK
• Cash Position: Cash, cash equivalents, and marketable securities were $2,477.4 million as of
September 30, 2021, compared to $2,589.4 million as of June 30, 2021. The decrease in cash of
$112.0 million was primarily driven by cash used in operating activities to support ongoing
research and development of the Company’s clinical and pre-clinical programs.
• Revenue: Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to
$0.1 million for the third quarter of 2020. Collaboration revenue primarily consisted of revenue
recognized in connection with our collaboration agreements with Vertex.
• R&D Expenses: R&D expenses were $105.3 million for the third quarter of 2021, compared to
$71.0 million for the third quarter of 2020. The increase in expense was driven by the development
activities supporting the advancement of the hemoglobinopathies program and wholly-owned
immuno-oncology programs, as well as increased headcount and supporting facilities, related
expenses.
• G&A Expenses: General and administrative expenses were $24.4 million for the third quarter of
2021, compared to $21.5 million for the third quarter of 2020. The increase in general and
administrative expenses for the year was primarily driven by headcount-related expenses.
• Net Loss: Net loss was $127.2 million for the third quarter of 2021, compared to a net loss of
$92.4 million for the third quarter of 2020.
https://crisprtx.gcs-web.com/static-files/2b9c5e50-091f-4103-bc29-f7c87de56f6e
MACD: BEARISH CROSS
RSI: OVERSOLD
VOLUME: LOW
CURRENT SUPPORT @ 1.272 FIB
1.618 IS YOUR IMPULSE TARGET FOR A BREAK IN EITHER DIRECTION
Puzzled on this one honestly, looks like it wants to go lower, but we'll see at the weekly close. Keep an eye on the SPY index.
DYOR
PRACTICE RISK MANAGEMENT
GOOD LUCK
Not
Not
Dead cat bounce and an ema death crossNot
Making its way down to the 1.618 target @ about $72Not
Just about there...
İlgili yayınlar
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.